Using Novalung to Treat Respiratory and Cardiac Failure with Dr. David Thompson
About this Episode
A year ago, the FDA cleared a product for use in the U.S. called Novalung®, an extracorporeal membrane oxygenation system (ECMO). Listen as Dr. David Thompson, Vice President and Medical Director of Critical Care for the Renal Therapies Group, a division of Fresenius Medical Care North America, joins Field Notes to discuss successful experiences with the first ECMO system-FDA cleared for long-term use over six hours in patients with acute respiratory or acute cardiopulmonary failure.
Recent Episodes from Field Notes
Episode 49: Patient Resources for Patient Empowerment with DeShawn Dorsey and Kaelyn Bamford
Episode 48: Using Artificial Intelligence as a Tool: Part 2 with Dr. Luca and Dr. Monaghan
Episode 47: An Update on Transitional Care Units with Dr. Dinesh Chatoth and Derek Blankenship
Episode 46: Improving CAPD Culture in the United States with Michelle Carver
Episode 45: Using Artificial Intelligence as a Tool: Part 1
Episode 44: Seeing ESRD as a Form of Heart Disease with Dr. Charles Herzog and Dr. Christopher Chan
Episode 43: The War in Ukraine and Dialysis with Dr. Stefano Stuard and Dr. Volodymyr Novakivskyy
Episode 42: An Update on Transplant Medicine with Dr. Benjamin Hippen
April is National Donate Life Month, and during this time, we focus on raising awareness about transplantation and donation honor the people who have saved lives through the gift of donation. Tune in for this special episode today for an update on the latest in transplant medicine. Transplantation is the best method of treatment for many people with end stage kidney disease, when available and accessible. As a company, we prioritize expanding access to kidney transplantation and work to reduce the challenges facing patients as they work towards getting transplanted.